CMS Modifies Coverage for Implantable Pulmonary Artery Pressure Sensors in Heart Failure Management (NCD 378)

The Centers for Medicare & Medicaid Services has modified NCD 378, its national coverage determination for implantable pulmonary artery pressure sensors (IPAPS) used in heart failure management. This update establishes detailed Coverage with Evidence Development (CED) criteria that billing teams, cardiologists, and hospital outpatient departments must understand before submitting claims for these services. If your practice or facility implants or manages patients with PA pressure sensor technology, this policy change is high-priority reading.

Field Detail
Payer Centers for Medicare & Medicaid Services (CMS)
Policy Implantable Pulmonary Artery Pressure Sensors for Heart Failure Management
Policy Code NCD 378
Change Type Modified
Effective Date 2026-03-12
Impact Level High
Specialties Affected Cardiology, Electrophysiology, Interventional Cardiology, Hospital Outpatient, Inpatient Hospital
Key Action Audit your IPAPS patient selection and documentation workflows against CMS's updated seven-point patient criteria checklist before the March 2026 effective date.

What Changed: CMS NCD 378 and IPAPS Coverage Under CED

CMS is covering IPAPS for heart failure management—but exclusively under Coverage with Evidence Development. CED means Medicare will reimburse the implantation and ongoing management of these devices only when services are furnished as part of a CMS-approved clinical study. This is not unconditional coverage. Facilities and physicians that do not operate within an approved CED study protocol will not have a pathway to Medicare reimbursement under this NCD.

The policy applies across three benefit categories: inpatient hospital services, outpatient hospital services incident to a physician's service, and physicians' services. That breadth matters for billing—the same underlying coverage rules govern claims regardless of the setting in which the implant or management service occurs.

This modification is significant because it codifies specific, multi-layered eligibility requirements at the national level. Prior to this update, coverage was less clearly defined. Now, claims reviewers and auditors have an explicit checklist to apply.


IPAPS Medical Necessity Criteria: What CMS Requires

CMS has organized its coverage criteria into three distinct tiers: patient criteria, physician criteria, and CED study criteria. All three must be satisfied for coverage to apply.

Patient Criteria — Seven Required Conditions

A patient must meet all of the following to qualify for covered IPAPS implantation:

#Covered Indication
1

Diagnosis of chronic heart failure of at least three months' duration, with New York Heart Association (NYHA) functional Class II or III documented within the 30 days prior to implantation—regardless of left ventricular ejection fraction (LVEF).

2

History of HF hospitalization or urgent HF visit (emergency room or outpatient visit requiring IV diuretic therapy) within the past 12 months, or elevated natriuretic peptides within the past 30 days.

3

Guideline-directed medical therapy (GDMT) for at least three months, with the goal of achieving optimal or maximally-tolerated GDMT before implantation.

+ 4 more indications

Enter your email to unlock all tables — 100% free

Unlocks every table on this page. Free weekly digest included. By subscribing you agree to our Terms and Privacy Policy.

That last criterion is operationally critical. A patient admitted for acute decompensated heart failure (ADHF) cannot receive a covered implant during that same stay. Facilities will need intake and scheduling protocols that flag this restriction.

Physician Criteria — Specialty and Training Requirements

CMS sets separate requirements depending on the physician's role:

#Covered Indication
1Referring and managing physicians must be cardiologists with training and experience in heart failure management.
2Implanting physicians must have training and experience in pulmonary arterial catheterization and intervention.

These requirements directly affect credentialing documentation and referral workflows. A hospitalist or general internist managing a patient post-implant does not satisfy the managing physician requirement under this NCD. Make sure your post-implant care assignments reflect this.

CED Study Criteria — The Coverage Gating Requirement

Every covered IPAPS service must be furnished within the context of a CMS-approved CED study. The study protocol must include only patients meeting the criteria above, use only qualified practitioners, and meet specific data collection and outcomes reporting requirements. If your facility is not currently enrolled in or affiliated with an approved CED study, CMS coverage under NCD 378 is not available—period.

Revenue cycle teams should confirm CED study affiliation before scheduling any IPAPS procedure intended for Medicare billing.


Sample Version Diff Line-by-line changes
Previous VersionCurrent Version
Coverage is considered experimental and investigational for all indicationsCoverage is considered medically necessary when specific criteria are met
Prior authorization is not requiredPrior authorization is required for initial treatment
Documentation must include clinical historyDocumentation must include clinical history
+ 1 more indications

Enter your email to unlock all tables — 100% free

Unlocks every table on this page. Free weekly digest included. By subscribing you agree to our Terms and Privacy Policy.

Affected Codes

This policy does not list specific CPT or HCPCS codes. The NCD 378 policy document as published does not enumerate applicable billing codes. Billing teams should monitor the CMS NCD Manual and any associated transmittals for code-level guidance, and watch for contractor-level LCD policies that may map specific codes to this NCD.

When code-level guidance becomes available, PayerPolicy will update this post and alert subscribers.


Why This Policy Matters for Revenue Cycle Teams

The CED requirement is the single biggest claims risk embedded in this policy. Without documented enrollment in a CMS-approved study, claims will lack the foundational coverage basis CMS requires—leading to denials that cannot be corrected with additional clinical documentation alone.

Beyond the CED requirement, the seven-point patient criteria checklist creates audit exposure if documentation is incomplete. Every criterion needs to be explicitly supported in the medical record:

Each of these is a potential denial trigger if absent.


This policy is now in effect (since 2026-03-12). Verify your claims match the updated criteria above.

What Your Billing Team Should Do

#Action Item
1

Confirm CED study participation immediately. Contact your cardiology department and hospital administration before March 12, 2026 to verify whether your facility is affiliated with a CMS-approved IPAPS CED study. If not, identify the pathway to enrollment—or pause IPAPS procedures intended for Medicare billing until enrollment is confirmed.

2

Build a pre-implant documentation checklist. Create a seven-point checklist mapped directly to the patient criteria in NCD 378. This checklist should be completed and signed before any IPAPS procedure is scheduled, and the supporting documentation should be uploaded to the patient's chart. Include NYHA class assessment date, natriuretic peptide results or hospitalization records, GDMT start date, device evaluation records, and cardiovascular event history.

3

Audit physician credentialing against CMS requirements. Cross-reference your current list of physicians referring, managing, and implanting IPAPS patients against the specialty and training requirements in section B.2. Flag any gaps and work with your credentialing team to document compliance before the effective date.

+ 2 more action items

Enter your email to unlock all tables — 100% free

Unlocks every table on this page. Free weekly digest included. By subscribing you agree to our Terms and Privacy Policy.

Get the Full Picture

Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.

🔍 Search by any code 🔔 Real-time alerts 📊 Line-by-line diffs ⏰ Deadline tracking
Get Full Access → $99/mo · 14-day money-back guarantee